Biological Assembly 1  

 3D View: Structure

Global Symmetry: Dihedral - D2  (3D View)
Global Stoichiometry: Homo 4-mer - A4 

Biological assembly 1 assigned by authors and generated by PISA,PQS (software)

Macromolecule Content

• Total Structure Weight: 26.84 kDa 
• Atom Count: 1830 
• Residue Count: 229 
• Unique protein chains: 1

1DVQ

CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN

• DOI: 10.2210/pdb1DVQ/pdb

• Classification: HORMONE/GROWTH FACTOR
• Organism(s): Homo sapiens
• Expression System: Escherichia coli
• Mutation(s): No 


• Deposited: 2000-01-22 Released: 2001-01-22 
• Deposition Author(s): Klabunde, T., Petrassi, H.M., Oza, V.B., Kelly, J.W., Sacchettini, J.C.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.00 Å
• R-Value Free: 0.223 
• R-Value Work: 0.203 

Literature

Rational design of potent human transthyretin amyloid disease inhibitors.

Klabunde, T., Petrassi, H.M., Oza, V.B., Raman, P., Kelly, J.W., Sacchettini, J.C.

(2000) Nat Struct Biol 7: 312-321

• PubMed: 10742177 
• DOI: 10.1038/74082
• Structures With Same Primary Citation


• PubMed Abstract: 
  

The human amyloid disorders, familial amyloid polyneuropathy, familial amyloid cardiomyopathy and senile systemic amyloidosis, are caused by insoluble transthyretin (TTR) fibrils, which deposit in the peripheral nerves and heart tissue. Several nonsteroidal anti-inflammatory drugs and structurally similar compounds have been found to strongly inhibit the formation of TTR amyloid fibrils in vitro. These include flufenamic acid, diclofenac, flurbiprofen, and resveratrol. Crystal structures of the protein-drug complexes have been determined to allow detailed analyses of the protein-drug interactions that stabilize the native tetrameric conformation of TTR and inhibit the formation of amyloidogenic TTR. Using a structure-based drug design approach ortho-trifluormethylphenyl anthranilic acid and N-(meta-trifluoromethylphenyl) phenoxazine 4, 6-dicarboxylic acid have been discovered to be very potent and specific TTR fibril formation inhibitors. This research provides a rationale for a chemotherapeutic approach for the treatment of TTR-associated amyloid diseases.

---

Organizational Affiliation: 

Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas 77843, USA.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
TRANSTHYRETIN	A, B	124	Homo sapiens	Mutation(s): 0  Gene Names: TTR, PALB
Find proteins for P02766 (Homo sapiens) Explore P02766  Go to UniProtKB:  P02766
NIH Common Fund Data Resources
PHAROS  P02766 GTEx  ENSG00000118271

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.00 Å
• R-Value Free: 0.223 
• R-Value Work: 0.203 
• Space Group: P 2₁ 2₁ 2

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 42.85	α = 90
b = 85.8	β = 90
c = 64.8	γ = 90

Software Package:

Software Name	Purpose
CNS	refinement
DENZO	data reduction
SCALEPACK	data scaling
CNS	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2000-01-22 
• Released Date: 2001-01-22 
Deposition Author(s): Klabunde, T., Petrassi, H.M., Oza, V.B., Kelly, J.W., Sacchettini, J.C.

Revision History 

• Version 1.0: 2001-01-22
  Type: Initial release
  
• Version 1.1: 2008-04-27
  Changes: Version format compliance
• Version 1.2: 2011-07-13
  Changes: Derived calculations, Version format compliance